Bausch Health Companies Inc., together with wholly owned subsidiary Salix Pharmaceuticals Inc.’s licensor Alfasigma SpA, announced the filing of a lawsuit against Sandoz Inc. alleging patent infringement of 14 patents by the Novartis division’s submission of an Abbreviated New Drug Application for Xifaxan

(rifaximin) 550 mg tablets.

The U.S. FDA approved Aries Pharmaceuticals Inc.’s Aemcolo (rifamycin) for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.